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Meta-analyses of phase III trials have compellingly dem-
onstrated that non-vitamin K oral anticoagulants (NOACs), 
including rivaroxaban and apixaban alone and dabigatran as 
well as edoxaban, after parenteral anticoagulant induction, are 
as effective as, and probably safer than, standard treatment 
with heparin/warfarin of acute venous thromboembolism 
(VTE). The relative efficacy and safety of the NOACs seem 
consistent across a wide range of patients [1]. Moreover, the 
NOACs significantly simplify VTE treatment because they are 
administered at fixed doses without any dietary restrictions 
along with limited interactions with other drugs, and, notably, 
no routine anticoagulation monitoring is required [2]. Despite 
growing evidence for the favourable risk-benefit profile of 
NOACs compared to warfarin, few studies have assessed the 
impact of NOACs used for treatment of acute VTE in real life. 
The present study by Paczyńska et al. [3] could be of particular 
interest for Polish cardiologists by providing such data from 
a well-known Warsaw centre following an investigation involv-
ing 215 consecutive acute pulmonary embolism (PE) patients 
hospitalised in the years 2013–2014. The study shows that 
patients treated with rivaroxaban (following a maximum of 
three days’ heparin administration) compared with those 
receiving vitamin K antagonists (VKA) stayed in hospital for 
a shorter period of time both when they had simplified PE 
severity index (sPESI) = 0 and sPESI ≥ 1 [3]. To explain this 
observation, comparative analysis of demographic and clinical 
characteristics for the PE patients on rivaroxaban and those 
on the standard therapy is needed. One might expect that 
the choice of rivaroxaban over the standard treatment in this 
cohort is driven by lower age of patients, fewer comorbidities, 
absence of dual antiplatelet agents, and normal renal function. 
Danish nationwide data from 2011 to 2013 published recently 
documented the pattern of use of currently available NOAC 
and warfarin in patients with atrial fibrillation (AF) and dem-
onstrated that for this indication, NOAC are more commonly 
used in female subjects at older age and in those with prior 
stroke, and less commonly in subjects with a history of chronic 
kidney disease, myocardial infarction, and heart failure [4]. 
Even if the current cohort was younger (median, 65 years) than 
most AF populations treated with NOACs [2], but higher than 
the average age of patients in each clinical trial on NOACs in 
VTE (55–60 years) [5], most associations reported in AF could 
be applicable to the VTE patients, although prolonged use of 
low-molecular-weight heparins, not only when strongly indi-
cated, i.e. in cancer- or pregnancy-associated PE, is relatively 
common in Poland. From my experience, in 2015 NOACs are 
preferred over warfarin in patients of both sexes with low- and 
intermediate-risk acute PE at ages below 65 years in whom 
renal function is normal or slightly reduced and a history of 
gastrointestinal bleeding is negative (A. Undas, unpublished 
data). It would be extremely interesting to show which factors 
influenced the Warsaw doctors’ decisions to use rivaroxaban 
or the standard therapy, apart from high-risk PE in which 
preferentially heparins followed by VKA antivitamin K were 
most likely to be used. This issue is unclear after having read 
the paper by Paczyńska et al. [3]. Another issue that deserves 
comment is a temporal prescription pattern of rivaroxaban 
compared with warfarin or acenocoumarol throughout the 
two-year study period.
Current European Society of Cardiology guidelines on 
acute PE management do not endorse NOACs over warfarin. 
There is a consensus that the choice of anticoagulation regi-
men should be personalised based on the relative efficacy 
and safety of different agents across subgroups stratified by 
thrombotic and bleeding risk, as well as on other clinical 
factors, e.g. drug interactions or compliance. I encourage 
the authors to continue their study and extend follow-up to 
provide much-needed data on the outcomes of rivaroxaban 
versus standard therapy of PE in Poland. To optimise treat-
ment for acute PE in the real-world setting, further research 
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is warranted to identify PE patients who may preferentially be 
managed with rivaroxaban or other NOACs in order to ease 
the burden of this potentially lethal disease.
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